Back to Journals » Journal of Experimental Pharmacology » Volume 4

The therapeutic potential of RORγ modulators in the treatment of human disease

Authors Chang MR, Goswami, Mercer, Griffin P

Received 21 August 2012

Accepted for publication 11 September 2012

Published 12 October 2012 Volume 2012:4 Pages 141—148

DOI https://doi.org/10.2147/JEP.S27078

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


Mi Ra Chang,1 Devrishi Goswami,1 Becky A Mercer,2 Patrick R Griffin1,2

1
Department of Molecular Therapeutics, Scripps Florida, The Scripps Research Institute, Jupiter, FL, USA; 2Translational Research Institute, Scripps Florida, The Scripps Research Institute, Jupiter, FL, USA

Abstract: Nuclear receptors (NR) are ligand-regulated transcription factors that bind DNA in proximity to their target genes and exert their effects as a result of binding by small molecule ligands such as sterols, lipids, fatty acids, retinoids, and steroid hormones. The retinoic acid receptor-related orphan receptors or RORs (NR1F1–NR1F3) are nuclear receptors that regulate multiple cellular processes, including metabolism, cellular differentiation, and apoptosis, in a range of tissues and organs. These receptors bind as monomers to ROR response elements commonly called ROREs present in promoter regions of target genes and tether chromatin remodeling enzymes, facilitating recruitment of transcription machinery. Several recent reports have highlighted the potential role for RORs in human disease, and more importantly, studies have demonstrated that these receptors can be modulated by exogenous synthetic ligands, paving the way for development of novel therapeutics. Here we review the current status of synthetic ligand development as well as the structural aspects governing modulation of ROR signaling pathways as they relate to metabolic diseases and autoimmune disorders.

Keywords: retinoic acid receptor-related orphan receptors (ROR), nuclear receptor (NR)modulator, synthetic ligand, inverse agonists, metabolic disorder, autoimmune disorder, ligand-binding domain (LBD)

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]